Refludan / Lepirudin: Overview

Modified on 2009/10/14 21:52 by admin
Refludan, also known as Lepirudin, is an anticoagulant indicated for patients who have had a reaction to heparin that resulted in reduced platelets and associated blood clots. Refludan greatly diminishes the effects of both soluble and clot-bound thrombin (an enzyme that facilitates the clotting of blood), decreasing a patient's risk of heparin-induced thrombocytopenia (HIT), a disorder characterized by the persistent decrease in the number of blood platelets. Refludan was approved by the U.S. Food and Drug Administration in 1998 and is made by Aventis Pharmaceuticals.

Bleeding, often excessive, is the most common side effect of Refludan use. Patients have also reported abnormal liver function and allergic skin reactions.

In October 2002, the European Medicines Evaluation Agency (EMEA) reported that five patients had died of severe allergic reactions after taking Refludan. According to the EMEA, there have been seven reports of anaphylactic reactions, mainly occurring after re-exposure to the medication. Letters have reportedly been sent to physicians worldwide warning of the recent deaths.

See your doctor if you have experienced an adverse reaction after being administered Refludan. In addition, it may be important to contact an attorney who can help you protect your legal rights. Please keep in mind that there may be time limits within which you must commence suit.

See Also

  1. Blood Thinning Drugs: Overview
  2. Excessive Bleeding: Overview
  3. Liver Problems
  4. Skin Disorders: Overview
  Name Size